Opko Health (NASDAQ:OPK) has completed the acquisition of the privately held pharmaceutical company Cytochroma. This move adds two key products to Opko's portfolio, Replidea (CTAP101) and and Alpharen (Fermagate). The former is a vitamin D prohormone, and the latter is a non-absorbed phostphate binder. Both are used in the treatment of secondary hyperparathyroidism, a glandular condition, and are in phase 3 of their development.
The acquisition was first reported in January. Terms of the deal were not disclosed. Opko Health has been on something of a buyout streak lately; in February it announced it had completed the purchase of Brazilian company Silicon Comercio, Importacao E Exportacao de Produtos Farmaceuticos e Cosmeticos.
Fool contributor Eric Volkman and The Motley Fool have no position in Opko Health. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.